Alcohol use disorder (AUD) screening frequently involves questionnaires complemented by laboratory work to monitor alcohol use and/or evaluate AUD-associated complications. Here we suggest that measuring aldehyde-induced DNA and protein adducts produced during alcohol metabolism may lead to earlier detection of AUD and AUD-associated complications compared with existing biomarkers. Use of aldehyde-induced adducts to monitor AUD may also be important when considering that approximately 540 million people bear a genetic variant of aldehyde dehydrogenase 2 (ALDH2) predisposing this population to aldehyde-induced toxicity with alcohol use. We posit that measuring aldehyde-induced adducts may provide a means to improve precision medicine approaches, taking into account lifestyle choices and genetics to evaluate AUD and AUD-associated complications.

饮酒障碍（AUD）筛查通常涉及以实验室工作为辅的问卷调查，以监测饮酒和/或评估AUD相关并发症。在这里，我们建议与现有的生物标志物相比，测量在酒精代谢过程中产生的醛诱导的DNA和蛋白质加合物可能会导致AUD和AUD相关并发症的早期检测。考虑到大约5.4亿人携带醛脱氢酶2（ALDH2）的遗传变异，使用醛诱导的加合物监测AUD也可能很重要。），使这些人群容易因饮酒而产生醛诱导的毒性。我们认为，考虑到生活方式的选择和遗传学来评估AUD和AUD相关并发症，测量醛诱导的加合物可能会提供一种改进精密医学方法的方法。